Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. Export

@article{citeulike:349490, abstract = {BACKGROUND: Following vaccination with 23-valent pneumococcal polysaccharide vaccine (PPV), pneumococcal antibody levels decline to prevaccination levels within 6-10 years. The Advisory Committee on Immunization Practices does not recommend routine revaccination because data on the safety and effectiveness of additional doses are insufficient. METHODS: To determine whether medically attended adverse events occur more frequently after the third dose of PPV than after the first or second dose, we performed a retrospective review of medical records from a computer database for health care facilities that serve more than one-half of the Alaska Native population. All persons who had received > or = 3 PPV doses (n = 179) were included in the review, as were a randomly selected comparison group of 181 persons who had received 1 or 2 doses. RESULTS: Only 1 (0.55\%) of 179 persons who had received > or = 3 PPV doses and 4 (2.76\%) of 181 persons in the comparison group had a medically attended adverse event, and no severe adverse events were recorded. CONCLUSION: We found no difference in the risk of medically attended adverse events following > or = 3 doses of PPV, compared with 1 or 2 doses.}, address = {National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. fwalker@cdc.gov}, author = {Walker, F. J. and Singleton, R. J. and Bulkow, L. R. and Strikas, R. A. and Butler, J. C.}, citeulike-article-id = {349490}, citeulike-linkout-0 = {http://dx.doi.org/10.1086/430305}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/15909258}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=15909258}, day = {15}, doi = {10.1086/430305}, issn = {1537-6591}, journal = {Clin Infect Dis}, keywords = {pneumovax, revaccination, vaccine}, month = {June}, number = {12}, pages = {1730--1735}, posted-at = {2005-10-12 21:52:39}, priority = {3}, title = {Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska.}, url = {http://dx.doi.org/10.1086/430305}, volume = {40}, year = {2005} }

TY - JOUR ID - citeulike:349490 L3 - citeulike-article-id:349490 N2 - BACKGROUND: Following vaccination with 23-valent pneumococcal polysaccharide vaccine (PPV), pneumococcal antibody levels decline to prevaccination levels within 6-10 years. The Advisory Committee on Immunization Practices does not recommend routine revaccination because data on the safety and effectiveness of additional doses are insufficient. METHODS: To determine whether medically attended adverse events occur more frequently after the third dose of PPV than after the first or second dose, we performed a retrospective review of medical records from a computer database for health care facilities that serve more than one-half of the Alaska Native population. All persons who had received > or = 3 PPV doses (n = 179) were included in the review, as were a randomly selected comparison group of 181 persons who had received 1 or 2 doses. RESULTS: Only 1 (0.55%) of 179 persons who had received > or = 3 PPV doses and 4 (2.76%) of 181 persons in the comparison group had a medically attended adverse event, and no severe adverse events were recorded. CONCLUSION: We found no difference in the risk of medically attended adverse events following > or = 3 doses of PPV, compared with 1 or 2 doses. IS - 12 JF - Clin Infect Dis SN - 1537-6591 AD - National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. fwalker@cdc.gov EP - 1735 TI - Reactions after 3 or more doses of pneumococcal polysaccharide vaccine in adults in Alaska. VL - 40 SP - 1730 KW - pneumovax KW - revaccination KW - vaccine AU - Walker, FJ AU - Singleton, RJ AU - Bulkow, LR AU - Strikas, RA AU - Butler, JC PY - 2005/06/15/ UR - http://dx.doi.org/10.1086/430305 ER -